Mannitab Pharma Specialities Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
as on 08-11-2024
- Paid Up Capital ₹ 0.30 M
as on 08-11-2024
- Company Age 2 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
About Mannitab Pharma Specialities
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 0.30 M, as per Ministry of Corporate Affairs (MCA) records.
Dineshkumar Lodha, Rushabh Lodha, Sriprakash Krishnan, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24290MH2022PTC381884
- Company No.
381884
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
02 May 2022
- Date of AGM
03 Nov 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Nashik, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Mannitab Pharma Specialities?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Dineshkumar Lodha  | Director | 02-May-2022 | Current |
| Rushabh Lodha | Director | 02-May-2022 | Current |
| Sriprakash Krishnan | Director | 01-Dec-2022 | Current |
Suk Kim  | Director | 01-Dec-2022 | Current |
Jason Payant  | Director | 01-Dec-2022 | Current |
Financial Performance of Mannitab Pharma Specialities.
Mannitab Pharma Specialities Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Mannitab Pharma Specialities?
In 2023, Mannitab Pharma Specialities had a promoter holding of 35.00% and a public holding of 65.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
M B Sugars And Pharmaceuticals Private LimitedActive 28 years 10 monthsDineshkumar Lodha and Rushabh Lodha are mutual person
Amishi Drugs And Chemicals Private LimitedActive 19 years 1 monthSriprakash Krishnan and Suk Kim are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Mannitab Pharma Specialities?
Mannitab Pharma Specialities has a workforce of 14 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Mannitab Pharma Specialities, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Mannitab Pharma Specialities's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
